The drug being tested in this survey is called Leuprorelin for Injection Kit 22.5 mg. Leuprorelin is being tested to treat people who have premenopausal breast cancer.~This survey will look at the safety in patients with premenopausal breast cancer receiving the drug in the routine clinical setting.~The survey will enroll approximately 300 patients.~- Leuprorelin~This multi-center survey will be conducted in Japan.
The purpose of this survey is to evaluate the safety in patients with premenopausal breast cancer receiving Leuprorelin in the routine clinical setting.